Imunon, Inc. (IMNN) Form 8-K — Oct 21, 2026
Imunon has agreed to sell its ThermoDox asset — a heat-activated liposomal doxorubicin — to VoxelDox Therapeutics, which plans to develop it for glioblastoma. In exchange, Imunon would receive a 4.76% equity stake in VoxelDox, up to $16.5 million in milestones, and royalties of 3.5% to 6% on net sales. The deal is contingent on VoxelDox raising at least $2.5 million; without that financing, the transaction will not close and Imunon receives no consideration. Any milestone or royalty value also depends on VoxelDox successfully developing and commercializing the asset.
Key figures
- Deal Value Usd
- 16500000
- Royalty range
- 3.5%-6% of net sales
- Consultant vesting
- 36 months monthly
- Financing contingency
- $2.5 million
- Consultant equity each
- 2.38% of fully diluted capitalization
- Equity stake in voxeldox
- 4.76% of fully diluted capitalization
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.